28 results on '"Del Poeta Giovanni"'
Search Results
2. ARHGDIA, a mutant TP53-associated Rho GDP dissociation inhibitor, is over-expressed in gene expression profiles of TP53 disrupted chronic lymphocytic leukaemia cells
3. Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia
4. B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage
5. MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3
6. Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38+CD49d+ chronic lymphocytic leukaemia cells
7. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia
8. IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia
9. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study
10. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias
11. FLUORESCENCE IN SITU HYBRIDIZATION AND CONVENTIONAL CYTOGENETICS FOR THE DIAGNOSIS OF 11Q23+/MLL+ TRANSLOCATION IN LEUKAEMIA
12. P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia
13. Venetoclax in CLL patients who progress after B‐cell Receptor inhibitor treatment: a retrospective multi‐centre Italian experience
14. BiallelicBIRC 3inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease
15. NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types
16. Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.
17. NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.
18. ARHGDIA, a mutant TP53-associated Rho GDP dissociation inhibitor, is over-expressed in gene expression profiles ofTP53disrupted chronic lymphocytic leukaemia cells
19. Clinical significance of c.7544-7545 delCTNOTCH1mutation in chronic lymphocytic leukaemia
20. IGHD3-3fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia
21. Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38+CD49d+chronic lymphocytic leukaemia cells
22. Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+ /mll + translocation in leukaemia
23. Clinical significance of c.7544-7545 del CT NOTCH1 mutation in chronic lymphocytic leukaemia.
24. Analysis of IgVH gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery.
25. research paper CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias.
26. MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53wild-type CLL with a poor cytotoxic response to Nutlin-3.
27. Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+ /mll + translocation in leukaemia.
28. Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38+CD49d+ chronic lymphocytic leukaemia cells.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.